Hemostasis is a remarkable and a remarkably complex mechanism. It can maintain blood in a fluid state intravascularly but very quickly changes blood to a jellylike mass upon disruption of the vasculature. This review will give a synopsis of the 3 phases of hemostasis: platelet, vascular, and coagulation. Fibrinolysis and control mechanisms of hemostasis will also be covered. In addition, brief descriptions of the clinical and laboratory evaluation of patients and the diagnosis of bleeding disorders will be presented.
Baumgartner HR, Tschopp TB, and Meyer D. (1980). Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Br. J. Haematol. 44: 127-139.
2.
Baumgartner HR, Turitto V., and Weiss HJ (1980). Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. J. Lab. Clin. Med. 95: 208-221.
3.
Biggs R. and Nossel HL (1961). Tissue extract and the contact reaction in blood coagulation. Thromb. Diath. Haemorrh. 6: 1-14.
4.
Boon GD and Rebar AH (1989). The clinical approach to disorders of hemostasis . In: Textbook of Veterinary Internal Medicine, SJ Ettinger (ed). W. B. Saunders, Philadelphia, pp. 105-107.
5.
Brigenshaw GF and Shanberge JN (1974). Identification of two distinct heparin cofactors in human plasma: Separation and partial purification . Arch. Biochem. Biophys. 161: 683-690.
6.
Brigenshaw GF and Shanberge JN (1974). Identification of two distinct heparin cofactors in human plasma: II. Inhibition of thrombin and activated factor X. Thromb. Res. 4: 463-477.
7.
Broze GJ and Majerus PW (1980). Purification and properties of human coagulation factor VII. J. Biol. Chem. 255: 1242-1247.
8.
Bykowska K., Levin EG, Rijken DC, Loskutoff DJ, and Collen D. (1982). Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells. Biochim. Biophys. Acta703: 113-115.
9.
Capel-Edwards K. and Hall DE (1968). Factor VII deficiency in the beagle dog. Lab. Anim. 2: 105-112.
10.
Chan V. and Chan TK (1979). Antithrombin III in fresh and cultured human endothelial cells: A natural anticoagulant from the vascular endothelium. Thromb. Res. 15: 209-213.
11.
Charo IF, Feinman RD, and Detwiler TC (1977). Interrelations of platelet aggregation and secretion . J. Clin. Invest. 60: 866-873.
12.
Clouse LH and Comp PC (1986). The regulation of hemostasis: The protein C system. N. Engl. J. Med. 314: 1298-1304.
13.
Colman RW (1974). Formation of human plasma kinin. N. Engl. J. Med. 291: 509-515.
14.
Cramer EM, Meyer D., le Menn R., and Breton-Gorius J. (1985). Eccentric localization of von Willebrand factor in an internal structure of platelet βαβ-granule resembling that of Weibel-Palade bodies. Blood66: 710-713.
15.
Davie EW and Ratnoff OD (1964). Waterfall sequence for intrinsic blood clotting . Science145: 1310-1312.
16.
Domer JL and Bass VD (1974). Normal prothrombin time and partial thromboplastin times of the dog. J. Am. Anim. Hosp. Assoc. 10: 412-414.
17.
Eastman JR, Triplett DA, and Nowakowski AR (1983). Inherited factor X deficiency: Presentation of a case with etiologic and treatment considerations. Oral Surg. Oral Med. Oral Pathol. 56: 461-466.
Esmon CT, Johnson AE, and Esmon NL (1991). Initiation of the protein C pathway. Ann. N. Y. Acad. Sci. 614: 30-43.
20.
Francis CW and Marder VJ (1990). Mechanisms of fibrinolysis. In: Hematology, WJ Williams, E Beutler, AJ Erslev , and MA Lichtman (eds). McGraw-Hill, New York, pp. 1313-1321.
21.
Fujikawa K. , Legaz ME, Kato H., and Davie EW (1974). The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin anctecedent). Biochemistry13: 4508-4516.
22.
Furie B. and Furie BC (1991). Molecular basis of γ-carboxylation: Role of the propeptide in the vitamin K-dependent proteins. Ann. N. Y. Acad. Sci. 614:1-10.
23.
Furie B. and Furie BC (1992). Molecular and cellular biology of blood coagulation . N. Engl. J. Med. 326: 800-806.
24.
Gailani D. and Broze GJ Jr (1991). Factor XI activation in a revised model of blood coagulation. Science253: 909-912.
25.
Garner R., Hermoso-Perez C., and Conning DM (1967). Factor VII deficiency in beagle dog plasma and its use in the assay of human factor VII. Nature ( London) 216: 1130-1131.
26.
George JN and Onofre AR (1982). Human platelet surface binding of endogenous secreted factor VIIIvon Willebrand factor and platelet factor 4. Blood59: 194-197.
27.
Girma J.-P, Kalafatis M., Pietu G., Lavergne J-M., Chopek MW, Edgington TS, and Meyer D. (1986). Mapping of distinct von Willebrand factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies. Blood67: 1356-1366.
28.
Goulian M. and Beck WS (1965). The partial thromboplastin time test. Am. J. Clin. Pathol. 35: 97-103.
29.
Griffith MJ , Carraway T., White GC, and Dombrose FA (1983). Heparin cofactor activities in a family with hereditary antithrombin III deficiency: Evidence for a second heparin cofactor in human plasma. Blood61: 111-118.
30.
Harms C. (1978). Laboratory evaluation of platelet function. In: Platelet Function: Laboratory Evaluation and Clinical Application , DA Triplett (ed). American Society of Clinical Pathologists, Chicago , pp. 35-61.
31.
Hathaway WE , Belhasen LP, and Hathaway HS (1965). Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies and physicochemical properties. Blood26: 521-532.
32.
Holmsen H. (1979). Secretable storage pools in platelets. Annu. Rev. Med. 30: 119-134.
33.
Houdijk WPM , Sakariassen KS, Nievelstein PFEM, and Sixma JJ (1983). Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III. J. Clin. Invest. 75: 531-540.
34.
Hougie C., McPherson RA, and Aronson L. (1975). Passovoy factor: A hitherto unrecognised factor necessary for haemostasis. Lancetii: 290-291.
35.
Hougie C., McPherson RA, Brown JE, Lakin-Thomas PL, Melaragno A., Aronson L., and Baugh RF (1978). The passovoy defect: Further characterization of a hereditary hemorrhagic diathesis. N. Engl. J. Med. 298: 1045-1048.
36.
Hovig T., Dodds WJ, Rowsell HC, and Mustard JF (1968). The transformation of hemostatic platelet plugs in normal and factor IX deficient dogs. Am. J. Pathol. 53: 355-362.
37.
Hoyer LW (1981). The factor VIII complex: Structure and function . Blood58: 1-13.
38.
Huang EM and Detwiler TC (1986). Stimulus-response coupling mechanisms. In: Biochemistry of Platelets, DR Phillips and MA Shuman (eds). Academic Press, Orlando, Florida, pp. 1-68.
39.
Hultin MB (1982). Role of human factor VIII in factor X activation . J. Clin. Invest. 69: 950-958.
40.
Hultin MB (1985). Modulation of thrombin-mediated activation of factor VIII:C by calcium ions, phospholipid, and platelets. Blood66: 53-58.
41.
Hultin MB and Nemerson Y. (1978). Activation of factor X by factors IXa and VIII; a specific assay for factor IXa in the presence of thrombin-activated factor VIII. Blood52: 928-940.
42.
Jaffe EA, Hoyer LW, and Nachman RL (1974). Synthesis of von Willebrand factor by cultured human endothelial cells. Proc. Natl. Acad. Sci. USA71: 1906-1909.
43.
Johnson AR and Erdos EG (1977). Metabolism of vasoactive peptides by human endothelial cells in culture: Angiotensin I converting enzyme (kininase II) and angiotensinase . J. Clin. Invest. 59: 684-695.
44.
Kaplan DR, Chao FC, Stiles CD, Antoniades HN, and Scher CD (1979). Platelet βαβ granules contain a growth factor for fibroblasts. Blood53: 1043-1052.
45.
Karpatkin M. , Howard L., and Karpatkin S. (1984). Studies of the origin of platelet-associated fibrinogen. J. Lab. Clin. Med. 104: 223-237.
46.
Kelleher JF Jr, Gomperts E., Davis W., Steingart R., Miller R., and Bessette J. (1986). Selection for replacement therapy for patients with severe factor VII deficiency . Am. J. Pediatr. Hematol. Oncol. 8: 318-323.
47.
Koedam JA, Meijers JCM, Sixma JJ, and Bouma BN (1988). Inactivation of human factor VIII by activated protein C. J. Clin. Invest. 82: 1236-1243.
48.
Kok P. and Astrup T. (1969). Isolation and purification of a tissue plasminogen activator and its comparison with urokinase. Blood8: 79-86.
49.
Koutts J., Walsh PN, Plow EF, Fenton JW, Bouma BN, and Zimmerman TS (1978). Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J. Clin. Invest. 62: 1255-1263.
50.
Kroll MH and Schafer AI (1989). Biochemical mechanisms of platelet activation . Blood74: 1181-1195.
51.
Lebreton de Vonne T. and Mouray H. (1978). Human α2-macroglobulin and its antitrypsic and antithrombin activities in serum and plasma. Clin. Chem. Acta90: 83-85.
52.
Levin EG, Marzec U., Anderson J., and Harker LA (1984). Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J. Clin. Invest . 74: 1988-1995.
53.
Lilly LS, Pratt RE, Alexander RW, Larson DM, Ellison KE, Gimbrone MA, and Dzau VJ (1985). Renin expression by vascular endothelial cells in culture. Circ. Res. 57: 312-318.
54.
Liu CY, Scott CF, Bagdasarian A.Pierce JV, Kaplan AP, and Colman RW (1977). Potentiation of the function of hageman factor fragments by high molecular weight kininogen. J. Clin. Invest . 60: 7-17.
55.
MacFarlane RG (1964). An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature (London) 202: 498-499.
56.
Majerus PW, Bansal VS, Lips DL, Ross TA, Mitchell CA, Caldwell KK, and Cunningham TW (1991). The phosphatidylinositol pathway of platelets and vascular cells. Ann. N. Y. Acad. Sci. 614: 44-50.
57.
Mann KG, Bovill EG, and Krishnaswamy S. (1991). Surface-dependent reactions in the propagation phase of blood coagulation. Ann. N. Y. Acad. Sci. 614: 63-75.
58.
Marmion PJ (1983). Passovoy defect: A cause of severe operative hemorrhage in obstetrics and gynecology. Am. J. Obstet. Gynecol. 145: 634-636.
59.
Maruyama I. , Bell CE, and Majerus PW (1985). Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J. Cell Biol. 101: 363-371.
60.
Meier HL, Pierce JV, Colman RW, and Kaplan AP (1977). Activation and function of human hageman factor: The role of high molecular weight kininogen and prekallikrein. J. Clin. Invest. 60: 18-31.
61.
Mertens K., van Wijngaarden A., and Bertina RM (1985). The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb. Haemost. 54: 654-660.
62.
Moncada S., Gryglewski R., Bunting S., and Vane JR (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation . Nature (London) 263: 663-665.
63.
Nachman R., Levine R., and Jaffe EA (1977). Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J. Clin. Invest. 60: 914-921.
64.
Nelsestuen GL (1978). Interactions of vitamin K-dependent proteins with calcium ions and phospholipid membranes. Fed. Proc. 37: 2621-2625.
65.
Nemerson Y. (1966). The reaction between bovine brain tissue factor and factors VII and X. Biochemistry5: 601-608.
66.
Nemerson Y. (1990). Sequence of coagulation reactions. In: Hematology, WJ Williams, E Beutler, AJ Erslev , and MA Lichtman (eds). McGraw-Hill, New York, pp. 1295-1304.
67.
Nilsson HL (1992). Von Willebrand's disease. Eur. J. Haematol. 48: 127-141.
68.
Olson RE, Houser RM, Searcey MT, Gardner EJ, Scheinbuks J., Rao GNS, Jones JP, and Hall AL (1978). Nature of the vitamin K-dependent CO2 fixation in microsomal membranes. Fed. Proc. 37: 2610-2614.
69.
Osterud B. (1984). Activation pathways of the coagulation system in normal haemostasis. Scand. J. Haematol. 32: 337-345.
70.
Osterud B. and Rapaport SI (1977). Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation . Proc. Natl. Acad. Sci. USA74: 5260-5264.
71.
Osterud B., Rapaport SI, and Lavine KK (1977). Factor V activity of platelets: Evidence for an activated factor V molecule and for a platelet activator. Blood49: 819-834.
72.
Parker MT, Turrentine MA, and Johnson GS (1991). Von Willebrand factor in lysates of washed canine platelets. Am. J. Vet. Res. 52: 119-125.
73.
Piotrowicz RS, Orchekowski RP, Nugent DJ, Yamada KY, and Kunicki TJ (1988). Glycoprotein Ic-IIa functions as an activation-independent fibronectin receptor on human platelets. J. Cell Biol. 106: 1359-1364.
74.
Proctor RR and Rapaport SI (1961). The partial thromboplastin time with kaolin: A simple screening test for first stage plasma clotting factor deficiencies . Am. J. Clin. Pathol. 36: 212-219.
75.
Radcliffe R. and Nemerson Y. (1975). Activation and control of factor VII by activated factor X and thrombin. J. Biol. Chem. 250: 388-395.
76.
Radcliffe R. and Nemerson Y. (1976). Mechanism of activation of bovine factor VII. J. Biol. Chem. 251: 4797-4802.
77.
Rakoczi I., Wiman B., and Collen D. (1978). On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim. Biophys. Acta540: 295-300.
78.
Ranby M. (1982.) Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim. Biophys. Acta704: 461-469.
79.
Rebar AH and Boon GD (1981). An approach to the diagnosis of bleeding disorders in the dog. J. Am. Anim. Hosp. Assoc. 17: 227-232.
80.
Revak SD, Cochrane CG, Bouma BN, and Griffin JH (1978). Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J. Exp. Med. 147: 719-729.
81.
Roberts HR and Foster PA (1987). Inherited disorders of the prothrombin conversion . In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, RW Colman, J Hirsh, VJ Marder , and EW Salzman (eds). Lippincott, Philadelphia, pp. 162-181.
82.
Roberts HR and Lozier JN (1992). New perspectives on the coagulation cascade. Hosp. Pract.97-112.
83.
Rodgers GM and Shuman MA (1983). Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc. Natl. Acad. Sci. USA80: 7001-7005.
84.
Roskam J., Hugues J., Bounameaux Y., and Salmon J. (1959). The part played by platelets in the formation of an efficient hemostatic plug. Thromb. Diath. Haemorrh. 3: 510-517.
85.
Saito H., Goldsmith G., and Ratnoff OD (1974). Fletcher factor activity in plasmas of various species. Proc. Soc. Exp. Biol. Med. 147: 519-523.
86.
Sakata Y., Mimuro J., and Aoki N. (1984). Differential binding of plasminogen to crosslinked and noncrosslinked fibrins: Its significance in hemostatic defect in factor XIII deficiency. Blood63: 1393-1401.
87.
Sander HJ, Slot JW, Bouma BN, Bolhuis PA, Pepper DS, and Sixma JJ (1983). Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J. Clin. Invest. 72: 1277-1287.
88.
Shuman MA and Greenberg CS (1986). Platelet regulation of thrombus formation. In: Biochemistry of Platelets, DR Phillips and MA Shuman (eds). Academic Press, Orlando, Florida, pp. 319-346.
89.
Sims PJ, Faioni EM, Wiedmer T., and Shattil SM (1988). Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263: 18205-18212.
90.
Sixma JJ and Wester J. (1977). The hemostatic plug. Semin. Hematol . 14: 265-299.
91.
Sporn LA, Chavin SI, Marder VJ, and Wagner DD (1985). Biosynthesis of von Willebrand protein by human megakaryocytes. J. Clin. Invest. 76:1102-1106.
92.
Stalder M., Hauert J., Kruithof EKO, and Bachman F. (1985). Release of vascular plasminogen activator (v-PA) after venous stasis: Electrophoretic-zymographic analysis of free and complexed v-PA. Br. J. Haematol. 61: 169-176.
93.
Stenberg PE and Bainton DF (1986). Storage organelles in platelets and megakaryocytes . In: Biochemistry of Platelets, DR Phillips and MA Shuman (eds). Academic Press, Orlando, Florida , pp. 257-294.
94.
Sussman II and Rand JH (1982). Subendothelial deposition of von Willebrand's factor requires the presence of endothelial cells. J. Lab. Clin. Med. 100: 526-532.
95.
Suttie JW, Larson AE, Canfield LM, and Carlisle TL (1978). Relationship between vitamin K-dependent carboxylation and vitamin K epoxidation. Fed. Proc. 37: 2605-2609.
96.
Thompson RE , Mandel R. Jr, and Kaplan AP (1977). Association of factor XI and high molecular weight kininogen in human plasma . J. Clin. Invest. 60:1376-1380.
97.
Tollefsen DM , Majerus PW, and Blank MK (1982). Heparin cofactor II. J. Biol. Chem. 257: 2162-2169.
98.
Tracy PB, Eide LL, Bowie EJW, and Mann KG (1982). Radioimmunoassay of factor V in human plasma and platelets. Blood60: 59-63.
99.
Tracy PB and Mann KG (1986). A model for assembly of coagulation factor complexes on cell surfaces: Prothrombin activation on platelets. In: Biochemistry of Platelets, DR Phillips and MA Shuman (eds). Academic Press, Orlando, Florida, pp. 295-318.
100.
Tracy PB, Peterson JM, Nesheim ME, McDuffie FC, and Mann KG (1979). Interaction of coagulation factor V and factor Va with platelets. J. Biol. Chem. 254: 10354-10361.
101.
Triantaphyllopoulos DC (1984). Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb. Haemost. 51: 232-235.
102.
Triplett DA (1978). The platelet: A review. In: Platelet Function: Laboratory Evaluation and Clinical Application, DA Triplett (ed). American Society of Clinical Pathologists, Chicago, pp. 1-33.
103.
Turitto VT , Weiss JH, Zimmerman TS, and Sussman II (1985). Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion . Blood65: 823-831.
104.
van Dieijen G., Tans G., Rosing J., and Hemker HC (1981). The role of phospholipid and factor VIIIa in the activation of bovine factor X. J. Biol. Chem. 256: 3433-3442.
105.
Waintraub SE and Sussman II (1985). The destabilization of factor VIII by a vitamin K dependent protein. Br. J. Haematol . 59: 579-586.
106.
Weiss HJ, Sussman II, and Hoyer LW (1977). Stabilization of factor VIII in plasma by the von Willebrand factor. J. Clin. Invest. 60: 390-404.
107.
Wencel-Drake JD, Painter RG, Zimmerman TS, and Ginsberg MH (1985). Ultrastructural localization of human platelet thrombospondin, fibrinogen, fibronectin, and von Willebrand factor in frozen thin section. Blood65:929-938.
108.
Wencel-Drake JD, Plow EF, Zimmerman TS, Painter RG, and Ginsberg MH (1984). Immunofluorescent localization of adhesive glycoproteins in resting and thrombin-stimulated platelets. Am. J. Pathol. 115: 156-164.
109.
Williams WJ and Norris DG (1966). Purification of a bovine plasma protein (factor VII) which is required for the activity of lung microsomes in blood coagulation. J. Biol. Chem. 241: 1847-1856.
110.
Wiman B., Mellbring G., and Ranby M. (1983). Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin. Chem. Acta127: 279-288.
111.
Zacharski LR, Delprete SA, Kisiel W., Hunt J., Cornell CJ, and Marrin CAS (1988). Atherosclerosis and coronary bypass surgery in hereditary factor VII deficiency . Am. J. Med. 84: 955-959.
112.
Zur M. and Nemerson Y. (1980). Kinetics of factor IX activation via the extrinsic pathway. J. Biol. Chem . 255: 5703-5707.
113.
Zur M. , Radcliffe RD, Oberdick J., and Nemerson Y. (1982). The dual role of factor VII in blood coagulation: Initiation and inhibition of a proteolytic system by a zymogen. J. Biol. Chem. 257: 5623-5631.
